Clinical

Dataset Information

0

Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer


ABSTRACT: The goal of this prospective clinical trial is to evaluate efficacy and safety of irinotecan liposomes for first-line treatment of advanced colorectal cancer. The primary endpoint is Objective response rate (ORR) per RECIST 1.1. The secondary endpoints are overall survival (OS), progression-free survival (PFS), disease control rate (DCR) and safety based on NCI-CTCAE 5.0

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 68175 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2021-03-01 | GSE147377 | GEO
2022-05-05 | GSE202156 | GEO
2023-12-31 | GSE243572 | GEO
2023-10-19 | GSE241876 | GEO
2022-09-06 | GSE212525 | GEO
2023-12-31 | GSE233112 | GEO
2024-07-30 | GSE273448 | GEO
| 2348431 | ecrin-mdr-crc
2024-02-22 | GSE249587 | GEO
2023-10-12 | E-MTAB-13423 | biostudies-arrayexpress